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Abstract
Background: The vaccinia-related kinase 1 (VRK1) protein, an activator of p53, can be proteolytically downregulated by an
indirect mechanism, which requires p53-dependent transcription.
Principal Findings: In this work we have biochemically characterized the contribution of several p53 transcriptional
cofactors with acetyl transferase activity to the induction of VRK1 downregulation that was used as a functional assay.
Downregulation of VRK1 induced by p53 is prevented in a dose dependent manner by either p300 or CBP, but not by PCAF,
used as transcriptional co-activators, suggesting that p53 has a different specificity depending on the relative level of these
transcriptional cofactors. This inhibition does not require p53 acetylation, since a p53 acetylation mutant also induces VRK1
downregulation. PCAF can not revert the VRK1 protection effect of p300, indicating that these two proteins do not compete
for a common factor needed to induce VRK1 downregulation. The protective effect is also induced by the C/H3 domain of
p300, a region implicated in binding to several transcription factors and SV40 large T antigen; but the protective effect is
lost when a mutant C/H3Del33 is used. The protective effect is a consequence of direct binding of the C/H3 domain to the
transactivation domain of p53. A similar downregulatory effect can also be detected with VRK2 protein.
Conclusions/Significance: Specific p53-dependent effects are determined by the availability and ratios of its transcriptional
cofactors. Specifically, the downregulation of VRK1/VRK2 protein levels, as a consequence of p53 accumulation, is thus
dependent on the levels of the p300/CBP protein available for transcriptional complexes, since in this context this cofactor
functions as a repressor of the effect. These observations point to the relevance of knowing the cofactor levels in order to
determine one effect or another.
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Introduction
The vaccinia-related kinases (VRK) form a group of three
proteins in the human kinome that diverged early from the casein
kinase I branch [1]. Several lines of evidence suggest that VRK1
contributes to cell division. Thus, VRK1 is highly expressed in
proliferating cell lines [2], and in embryonic development during
the expansion of the hematopoietic system [3]. In human biopsies
VRK1 is mainly detected in the amplifying compartment of
epithelial surfaces, where it co-localizes with several proliferation
markers [4]. Loss of human VRK1 by siRNA reduces cell division
[5], and in C. Elegans the inactivation of its homolog gene results
in embryonic death and arrested growth in adults [6].
The human vaccinia-related kinase 1 VRK1 phosphorylates
p53 uniquely in Thr18 [7,8] and induces its stabilization and
acetylation [5]. This specific phosphorylation contributes to p53
stabilization by interfering with binding to hdm2 [5,9,10], and
increases p53 binding to p300 and p53 acetylation [5]. Differently
acetylated p53 molecules may oligomerize with some differences in
their organization that can affect gene transcription specificity.
The interaction of p53 with hdm2 depends on its phosphorylation.
The persistent accumulation of p53 would result in a permanent
block to cell cycle progression or the cells will enter apoptosis, and
thus is not compatible with life. Therefore p53 levels are usually
low and its accumulation is transient. Precisely to prevent this
accumulation, p53 induces its main downregulatory protein
mdm2/hdm2 [11].
Since VRK1 contributes to p53 stabilization, some mechanism
of autoregulation between these two proteins is likely to function in
the cell and has been recently identified. In vivo there is an inverse
correlation between p53 and VRK1 levels in human tumor cell
lines [12]; furthermore in human fibroblast, the induction of DNA
damage by ultraviolet light and subsequent accumulation of p53 is
accompanied by a downregulation of endogenous VRK1 [12].
This downregulatory mechanism could be reproduced in trans-
fection experiments making it more accessible for characterization
[12], and is independent of the promoter used to express VRK1,
thus indicating it is an indirect effect [12]. The accumulated p53
regulates VRK1 protein level by proteolytic degradation, which is
mediated by an indirect mechanism that requires de novo gene
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also independent of a proteasome mediated pathway; this
mechanism is insensitive to proteasome inhibitors, and hdm2/
mdm2 is not implicated since it is also functional in mdm2
deficient cells [12]. This mechanism targets VRK1 to enter the
endosome-lysosome pathway where it is proteolytically downreg-
ulated [12]. These autoregulatory properties are altered when p53
is mutated; thus transcription-defective p53 mutants cause an
accumulation of VRK1 because its degradation mechanism can
not be induced [12], an observation that has been confirmed in
human lung squamous cell carcinomas containing mutations in
p53, which have very high levels of endogenous VRK1 [13].
Since this VRK1 downregulation requires p53 dependent
transcription [12], in this report we have used this VRK1
downregulation by p53 to determine the potential contribution of
different acetyl transferase cofactors of p53 that can modulate the
specificity of gene transcription, and for which VRK1 downreg-
ulation provides a functional assay. The tumor suppressor p53 has
different responses to a common stimulation depending on cell
type, which is likely to reflect a differential composition of
transcriptional complexes. The transcriptional activity of p53 is
regulated by interaction with transcriptional coactivators such as
the p300/CBP, or the PCAF (p300/CBP-associated factor) acetyl
transferases [14]. The sites acetylated in p53 are Lys373, Lys382
by p300/CBP and Lys320 by PCAF [15], which selectively
activate transcription [16]. The tumor suppressor p53 interacts
with p300 by two different regions, one located in the N-terminus
and required for nuclear export and degradation, and the other
near the C-terminal region, proximal to but different from the C/
H3 region, which is required for activation of transcription
[14,17]. The C/H3 region has an eighty percent homology to the
same region in CBP (CREB binding protein), but is not present in
PCAF. The C/H3 domain is an interaction region with many
different proteins such as viral proteins as adenovirus E1A or
SV40 large T antigen, or transcription factors such as MyoD, Fos,
c-Jun, and E2F [14,18].
In this work we have determined the requirement for the
contribution of co-transcriptional factors with acetyl transferase
activity and determined their contribution to the specificity of the
effect induced by p53 on the stability of VRK1. This would
indicate that some transcriptional cofactors, but not others will be
determinants of the effect. Among the three cofactors, p300, CBP
and PCAF that interact with p53, only the former two were able to
prevent this VRK1 downregulation. Complexes of p53 with
proteins having a C/H3 domain are not able to downregulate
VRK proteins.
Results
p300 and CBP protect VRK1 from its p53-induced
downregulation
The downregulation of VRK1 by p53 has been shown to be
dependent on p53-induced transcription of an unknown protein
that controls VRK1 proteolytic degradation [12]. Therefore it was
decided to identify the contribution of p53 transcriptional
cofactors to this process. p300 and CBP are p53 coactivators that
participate in its transcriptional activation by acetylation of Lys373
and Lys382 residues [14,19]. It has been previously reported that
VRK1 was able to increase p53 acetylation after its specific
phosphorylation on Thr-18 [5]. First, it was tested if p300 could
have any effect on the transcriptionally dependent downregulation
of VRK1 induced by p53. For this aim H1299 cells were
cotransfected with plasmids pCEFL-HA-VRK1, pCB6+p53 and
increasing amounts of pCMV-p300 (Fig. 1A). Surprisingly, as the
p300 protein level increased, it was accompanied by a parallel
increase in the protection of VRK1 degradation induced by p53
(Fig. 1A). To confirm that the effect requires the participation of
p53, the same experiment was performed in the absence of p53
(Fig. 1B). In this situation p300 over-expression by itself has no
effect on VRK1, or perhaps even induces a minor increase in its
levels. These results suggested an implication of the p300
coactivator in preventing VRK1 downregulation by p53. An
unknown connection between these proteins may occur or it might
be possible that the gene controlled by p53 that regulates VRK1
does not require p300 as coactivator and that unique over-
expression of p300 is sufficient to direct the transcriptional activity
of p53 to other targets and to abrogate the negative effect of p53
on VRK1 levels. The expression of actin was not affected by either
p53 or any of the cofactors.
P300 and CBP are two related proteins with an 80 per cent
homology suggesting many of their effects are probably similar.
Therefore it is likely that CBP could also protect VRK1 from
downregulation induced by p53; or alternatively detection of a
differential response would contribute to determine the specificity
of the effect. To distinguish between these two possibilities, a
similar set of experiments was performed. Increasing amounts of
CBP were able to protect VRK1 from downregulation induced by
p53 (Fig. 1C), and CBP by itself in the absence of p53 had no effect
on VRK1 levels (Fig. 1D). As a negative control the lack of effect
on another protein that it is not susceptible to this downregulation
mechanism was determined. Cells were transfected with a plasmid
expressing human TSG101 [20]. The levels of this transfected
protein, as well as that of the endogenous actin, are not
downregulated by p53 (Fig. 1E).
PCAF does not protect VRK1 from its p53-induced
downregulation
The protein PCAF is another acetyl transferase that also
functions as p53 cofactor, and acetylates p53 in a different residue,
Lys 320. Therefore, a similar experiment was performed using
plasmid pCI-Flag-PCAF, in this case the unique over-expression of
the PCAF protein together with p53 and VRK1, in a similar
experiment as the one with p300 in the previous section, did not
have any protective effect on VRK1 downregulation by p53
(Fig. 2A), and increasing levels of PCAF by itself also had no effect
on VRK1 (Fig. 2B). This confirms a specific involvement of p300/
CBP protein as a p53 coactivator, which is functionally different
form PCAF. It is possible that PCAF might be able to displace
p300 from the complex and thus prevent the effect of p300.
To determine if PCAF can compete with p300 in the induction
of VRK1 downregulation two types of experiments were
performed. First it was tested if increasing amounts of PCAF
were able to revert the protection induced by p300, as shown in
Fig 2C, PCAF does not revert the effect of p300. Next it was
determined if the lack of effect of PCAF could be prevented by
p300; increasing amounts of p300 even in the presence of PCAF
were able to induce protection of VRK1 (Fig. 2D). Thus it can be
concluded that PCAF does not compete with p300 for any factor
to induce the response to p53.
p53 phosphorylation mutants also induce VRK1
downregulation
Phosphorylation in the N-terminal region of p53 can modify the
interactions of p53 with other proteins and this can, in turn,
modify the transcriptional activity of p53 in response to different
types of cellular stimulation [21,22]. However, phosphorylation in
this region of p53 appears to be dispensable for the activation of
p300 Prevents VRK1 Degradation
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specificity of interactions with other proteins. Therefore the
potential effect of different phosphorylation mutants of p53, either
in its amino (DN has mutated the following residues: S6A, S9A,
S15A, T18A, S20A, S33A and S37A) or carboxy terminus (DC has
mutated the following residues: S315A, S371A, S376A, S378A,
S392A) [25], were tested to determine if they have any effect on
the p53 induction of VRK1 protein downregulation. Several p53
mutants affecting individual or all phosphorylatable residues were
also tested. All the p53 phosphorylation mutants, including
p53
T18D that mimics phosphorylation by VRK1 and prevents
interaction with hdm2 [12], induced a VRK1 downregulation like
the wild-type p53 (Fig. 3). In this experiment, a p53 mutant that is
transcriptionally inactive by mutation in the DNA binding
Figure 1. p300 and CBP protect VRK1 from p53-induced downregulation. (A) H1299 cells were transfected with pCB6+p53 (0.2 mg) and
pCEFL-HA-VRK1 (5 mg) with increasing amounts of pCMVb-p300-HA and 36 hours postransfection cell extracts were analyzed with the different
antibodies indicated in the legend. Normalized VRK1 protein levels are represented in the graphs. VRK1 and p300 were detected with an anti-HA
antibody. (B) p300 over-expression by itself does not have any effect on VRK1 protein levels. An experiment similar to that in part A, but in the
absence of p53 was performed. (C) H1299 cells were transfected with pCB6+p53 and pCEFL-HA-VRK1 with increasing amounts of pSG5-CBP and
36 hours postransfection cell extracts were analyzed with the different antibodies indicated in the legend. CBP was detected with a rabbit polyclonal
antibody. Normalized VRK1 protein levels are represented in the graphs. (D) CBP over-expression by itself does not have any effect on VRK1 protein
levels. An experiment similar to that in part C, but in the absence of p53 was performed. Each protein was detected in the immunoblots as indicated
in the methods section. (E). Negative control for lack of p53 effect. H1299 cells were transfected with pCEFL-HA-TSG101 (5 mg) and increasing
amounts of pCB6+p53 (0.2 mg). TSG101 was detected with an anti-HA antibody. The experiments were performed independently three times. The
quantifications corresponding to immunoblots with differences (parts A–D) are shown and presented in bar graphs.
doi:10.1371/journal.pone.0002649.g001
p300 Prevents VRK1 Degradation
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R280K, was included as a positive control for loss of
effect, and as expected [12] it did not induce a VRK1
downregulation (Fig. 3).
p300 prevents VRK1 downregulation induced by the
p53
L22Q/W23S mutant
The transactivation domain of p53 interacts with p300, and this
interaction is partially disrupted in the p53
L22Q/W23S conforma-
tional mutation [17], which has been shown to bind weakly to
p300, thus it is defective as a gene repressor and in apoptosis
induction [26]; but this mutant is still able to downregulate VRK1
[12]. Therefore it was tested if this downregulatory effect could be
prevented by p300, even if the direct interaction of p53–p300 is
impaired. For this aim H1299 cells were transfected with the
p53
L22Q/W23S plasmid and pCEFL-HA-VRK1 in the absence or
presence of p300 (Fig 4A). In this case p300 still protected VRK1,
although much less efficiently, from the downregulation induced
by p53
L22Q/W23S (Fig 4A). This observation is consistent with its
reduced interaction with p300. But this p53
L22Q/W23S mutant is
very inefficient in inducing VRK1 downregulation [12], thus there
is very little margin to detect a protection by p300.
Non acetylated p53 also induces downregulation of VRK1
The three proteins p300, CBP and PCAF are histone acetylases,
therefore one possibility is that their differential effect might be
mediated by acetylation of p53 in different residues. For this
purpose it was determined if the use of a p53 mutant, which has all
its six acetylated lysine residues in its oligomerization C-terminal
domain mutated, was still able to induce VRK1 downregulation.
This p53-6KR equally induced downregulation of VRK1
indicating that acetylation was not necessary, and that the effect
must be due to specific interactions in the p300 molecule (Fig. 4B).
Therefore it can be concluded that p53 induced downregulation of
VRK1 is not associated with the acetylation of p53.
The C/H3 region of p300 can block the p53-induced
downregulation of VRK1
The p300 molecule has two different regions of interaction with
other molecules. One of them is located near its N-terminal region
and is associated with p53 degradation, and requires participation
of hdm2/mdm2. The second p300 region of protein interactions is
more proximal to the C-terminus and is implicated in activation of
Figure 2. PCAF does not protect from p53-induced downregulation of VRK1. (A) PCAF over-expression does not exert any protective effect
on VRK1 downregulation by p53. H1299 cells were transfected with pCB6+p53 (0.2 mg) and pCEFL-HA-VRK1 (5 mg), and the experiment was carried
out like in Figure 1, but a PCAF expression plasmid was included instead of the p300 plasmid. VRK1 protein levels were quantified and shown in the
graph. PCAF was detected with an anti-Flag antibody. VRK1 was detected with an anti-HA antibody. The quantification of immunoblots is presented
in bar graphs. (B) PCAF over-expression by itself, in the absence of p53, does not have any effect on VRK1 protein levels. Normalized VRK1 protein
levels are represented in the graph. The quantification of immunoblots is presented in bar graphs. (C). Increasing amounts of PCAF are unable to
compete with p300 in its protection of VRK1 downregulation induced by p53. (D). Increasing amounts of p300 protect from p53-induced
downregulation of VRK1 independently of the presence of PCAF. The experiments were performed independently three times.
doi:10.1371/journal.pone.0002649.g002
p300 Prevents VRK1 Degradation
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86 per cent homology with CBP, is a region implicated in their
interactions with SV40 large T antigen, adenovirus E1A, PCAF,
Fos, E2F and c-Jun proteins [27]. The p300 HAT activity is
located in residues 1195 to 1921, but is lost if residues 1353–1355
and 1466–1467 are mutated or deleted [17]. Therefore two
different constructs expressing this p300 binding domain, p300-C/
H3-Flag (aa 1709–1913) and p300-C/H3-Del33-Flag (same
region but lacking aminoacids 1737–1809 required for binding
to the SV40 large T antigen) [17] do not have acetyl transferase
activity. Thus any effect will be a consequence of their protein
interaction and not of the enzymatic activity. Expression of the C/
H3 construct by itself was able to prevent the induction of VRK1
degradation by p53 (Fig. 5A), but this prevention was lost if the
deletion C/H3-Del33 defective in binding was used (Fig. 5B).
These results indicate that the possible interaction of p53 with the
C/H3 region (aminoacids 1709–1913) of p300 is enough to
change its transcriptional specificity, or compete for a common
factor shared with p53, and thus modifies the effects induced by a
p53 dependent mechanism. The effect is lost by deletion (Del33)
(aminoacids 1709–1913 without residues 1737–1836) of the
interaction region with SV40 large T antigen, a viral polymerase,
suggesting that the mechanism might be controlling the specificity
of the interaction of p300 with cellular polymerases and their
association or integration in transcriptional complexes.
Next it was determined if either PCAF or C/H3-Del33 could
compete in the protective effect mediated by either p300 of the C/
H3 domain (Fig. 6). The effect is shown in lanes 1 to 3, but neither
PCAF (lane 4) nor C/H3Del33 (line5) could revert the protection
mediated by p300. Next the protective effect of C/H3 (lane 6) was
not affected by either PCAF (lane 7) or C/H3Del33 (lane 8). The
last two lanes (9 and 10) are controls to show the lack of protection
of PCAF or C/H3Del33 by themselves.
The p300 C/H3 domain directly binds to the
transactivation domain of p53
A major difference between p300, CBP and PCAF is that the
first two proteins have a C/H3 domain. Although the role of C/
H3 as a binding region for p53 is not clear, and the evidence is
contradictory [14,17,18,28], C/H3 is located in within p300 C-
terminal region required for interaction with the SV40 large T
antigen and several transcription factors [17]. Therefore, it is
possible that the mechanism by which p300/CBP, or for that
matter their C/H3 domain blocks VRK1 downregulation might
be precisely because the C/H3 region directly interacts with p53
and thus prevents its effect. To test this possibility H1299 cells
were transfected with different constructs of wild-type p53, the
conformational mutant p53
L22Q/W23S,o rD40p53 isoform lacking
the first 40 amino acids of the transactivation domain [12,29]; and
their interaction with the C/H3 domain was determined in
immunoprecipitation experiments. The C/H3 domain interacted
with the wild-type p53, and this interaction was lost if it lacks the
transactivation domain, while the interaction was much weaker
with the conformational mutant p53
L22Q/W23S (Fig. 7), consistent
with its defective role as gene repressor [26], but retains other
functions in DNA repair [30]. These data are consistent with the
reduced VRK1 protection shown in previous experiments (Fig. 4).
These results suggest that binding of proteins by their C/H3
domain to the transactivation domain of p53 are likely to affect the
type of transcriptional complexes formed, and thus the specificity
of gene activation; implying that the one required to induce VRK1
downregulation is not activated when proteins with a C/H3
domain form part of the complex. The binding of the C/H3 to
p53 may be functioning as a dominant negative factor.
VRK2 isoforms are also downregulated by p53 and the
effect is prevented by p300 or chloroquine
The human VRK2 gene generates by alternative splicing two
isoforms of VRK2 of 508 (VRK2A) and 397 (VRK2B) aminoacids
respectively [31]. The two isoforms are identical in their first 396
aminoacids, thus VK2B is a variant that lacks the C-terminal
domain, which contains the membrane anchor of VRK2A
[31,32]. Both VRK2 isoforms have the conserved endosomal-
lysosomal target sequence, therefore it is highly likely that they
should also be downregulated by the same mechanism as VRK1
[12]. Furthermore VRK2 also phosphorylates p53 in the same
Figure 3. Effect of p53 phosphorylation mutants on the
downregulation of VRK1. The p53 aminoacid substitutions are
indicated in the diagram. At the top is shown the level of expression of
each p53 mutant and at the bottom is shown the quantification of the
blot. As positive control is included wild-type p53 that induces the
effect (second lane). As negative control for lack of effect the p53
R280K
mutant is also included. The constructs have mutated either individual,
or different combinations of residues as indicated in the legend, or
alternatively all p53 phosphorylation residues in the N-terminus
(substitutions of phosphorylable residues in the N-terminal region;
DN: S6A, S9A, S15A, T18A, S20A, S33A and S37A), the C-terminus
(substitutions of phosphorylable residues in the C-terminal region; DC:
S315A, S371A, S376A, S378A, S392A) and both (DN/DC, all phosphor-
ylatable residues in the N and C-terminal region are substituted). H1299
cells were transfected with 5 mg of pCEFL-HA-VRK1 and the indicated
p53 construct. The expression of the p53 constructs aimed to express
similar protein levels of all mutants. Cell extracts were prepared
36 hours after transfection and the levels of both proteins were
determined by western blot. The transfected VRK1 was detected with
an antibody specific for the HA epitope. p53 was detected with a
mixture of DO1 and Pab1801 antibodies. The experiments were
performed independently three times. The quantification correspond-
ing to the immunoblots shown and is presented in lower bar graphs.
doi:10.1371/journal.pone.0002649.g003
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(B). (A) H1299 cells were transfected with the indicated amounts of the p53
L22Q/W23S conformational mutant that prevents binding to acetyl
transferases as p300, 5 mg of pCEFL-HA-VRK1 and increasing amounts of p300. VRK1 was detected with an anti-HA antibody. (B). H1299 cells were
transfected with the indicated amounts of the p53-6KR acetylation mutant and 5 mg of pCEFL-HA-VRK1. Cell extracts were prepared 36 hours after
transfection and the levels of both proteins were determined by western blot. To the bottom is shown the quantification of the blots to illustrate the
changes in both proteins. The transfected VRK1 was detected with an antibody specific for the HA epitope. The experiments were performed
independently three times. The quantification corresponds to the immunoblots shown and is presented in bar graphs.
doi:10.1371/journal.pone.0002649.g004
Figure 5. Effect of the p300 C/H3 domain. (A) Effect of the complete p300 CH3 domain that lacks acetyl transferase activity. H1299 cells were
transfected with the indicated amounts of the p300-C/H3-Flag plasmid, pCB6+p53 (0.2 mg) and 5 mg of pCEFL-HA-VRK1. VRK1 was detected with an
anti-HA antibody. P300 was detected with an anti-Flag antibody. (B) Effect of the p300 C/H3Del33 domain lacking the residues required for
interaction with SV40 large T antigen. H1299 cells were transfected with the indicated amounts of the p300-C/H3-Del33-Flag plasmid pCB6+p53
(0.2 mg), and 5 mg of pCEFL-HA-VRK1. The CH3 domains were detected with an anti-Flag antibody. The experiments were independently performed
three times. The quantification corresponds to the immunoblots shown and is presented in bar graphs.
doi:10.1371/journal.pone.0002649.g005
p300 Prevents VRK1 Degradation
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isoforms, A (bound to the endoplasmic reticulum) and B (mostly
nuclear), were also downregulated by high levels of p53. H1299
cells were transfected with each of the VRK2 isoforms and high
levels of p53. The amount of p53 that induced downregulation of
VRK1 was also able to downregulate both isoforms of VRK2 (first
two lanes in Fig. 8A). In order to determine if the underlying
mechanism was the same, two experiments were performed. First
it was established if the level of p300 was also able to protect
VRK2 isoforms from downregulation. Cells were transfected with
increasing amounts of p300 in the presence of p53 at a level that
downregulated VRK2 isoforms. P300 was able to protect both
VRK2 isoforms from p53-induced downregulation in a p300 dose
dependent manner (Fig. 8A)
Next it was determined if VRK2 downregulation was also
sensitive to inhibitors of endosome-lysosome vesicular transport,
such as chloroquine. For this experiment cells were transfected
with a fixed amount of p53 that induces an almost complete
downregulation of both VRK2 isoforms, and the effect of an
increasing concentration of chloroquine was determined. Chloro-
quine inhibited in a dose-dependent manner the downregulation
of VRK2A and VRK2B induced by p53 (Fig. 8B). Therefore it
was concluded that VRK2A and B, like VRK1, protein levels were
down regulated by a similar mechanism that requires p53 and that
is sensitive to the level of p300, and to inhibitors of the endosome-
lysosome pathway.
VRK1 and VRK2 have multiple endocytic-lysosomal
regions
VRK1 has a region located between residues 304–320 that has
a consensus sequence for targeting VRK1 to the lysosomal-
endosomal pathway, which was shown to be the route of VRK1
proteolytic degradation induced by p53 [12]. Several VRK1
constructs spanning different regions of VRK1 were tested for
their downregulation induced by p53. All VRK1 deletion mutants
were downregulated (Fig. 9A). These results suggested that more
than one target sequence is likely to exist in the VRK1 protein.
VRK1 has an accessible endocytic and lysosomal target sequences
in region 304–320. However, other sequences for endosomal
targeting that are not normally exposed, but may be available in
the deletion proteins because probably they do not fold correctly
the globular kinase domain. VRK1 protein has several potential
regions for endocytic-lysosomal targeting (Fig. 9A). Additional
targeting sequences that can mediate interaction with the
endosomal-adaptor protein are located in positions 107–110,
126–129, 191–196, and 249–252, but they are not exposed
because they are embedded within the globular kinase domain;
however some may be exposed if in deletion constructs the protein
folding is not correct (Fig. 9A). Thus all deletion constructs have
more than one sequence that targets them to enter the endocytic
pathway if exposed, and this may explain why all of them are
sensitive to this downregulation.
Similarly different constructs of the human VRK2 proteins were
also downregulated by p53 and protected by the C/H3 domain of
p300 (Fig. 9B). These data indicate that there are at least two
Figure 6. PCAF or C/H3Del33 do not compete with p300 or C/
H3 in the protection of VRK1. H1299 cells were transfected with the
indicated amount of plasmids in different combinations. p300 was
detected with an antibody anti-p300 at 1:1000 dilution. PCAF, p300-C/
H3 and p300-C/H3Del33 were detected with an anti-flag antibody.
doi:10.1371/journal.pone.0002649.g006
Figure 7. p300 C/H3 domain directly binds to transactivation
domain of p53. H1299 cells were transfected with plasmids
expressing wild-type p53, pCB6+p53 (0,6 mg), its isoform lacking the
transactivation domain pCMV-D40p53 (5 mg) or the conformational
mutant pCMV-p53
L22Q/W23S (0,6 mg), in combination with plasmids
p300-C/H3-Flag (5 mg). At the top is shown the level of expression of
each construct in whole cell lysates that were used for immunoprecip-
itation. The Flag tagged proteins were immunoprecipitated with an anti
Flag polyclonal antibody, and the p53 bound was determined in an
immunoblot using anti p53 specific antibody (bottom gel). In the
immunoprecipitate C/H3 was detected with an anti-Flag monoclonal
antibody.
doi:10.1371/journal.pone.0002649.g007
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proteins for degradation. Analysis with ELM programs identifies
one of them in residues 422–425, but VRK2 has several additional
sequences than might bind the mu subunit of the adaptor protein
that may be exposed in VRK2 deletion constructs. These latter
sequences are evenly distributed throughout the sequence at
positions 44–47, 77–80, 116–119, 238–241 and 306–309 (Fig. 9B).
Discussion
The direct mechanism implicated in the downregulation of
VRK1 protein is mediated by a p53-dependent gene, since different
p53 mutants, including the most common mutations detected in
human cancers, which are not able to induce transcription does not
cause downregulation of VRK1 protein [12]. A mechanism that
was confirmed in human squamous cell lung carcinomas, where
those cases harboring p53 mutations presented very high levels of
VRK1 protein [33]. Furthermore, as shown in this work analysis of
p53 phosphorylation mutants in residues implicated in responses to
stress, which are not essential for transcription [23,24], have a
similar effect to that of wild-type p53 on VRK1 downregulation.
Thismechanism induces the targetingof VRK proteins to enter in a
pathway that result in their proteolytic downregulation; but the
mechanism by which VRK1, or VRK2 proteins are targeted is not
yet known. This downregulation of VRK1, or VRK2, induced by
p53 requires transcriptional activation of an intermediate gene that
is responsible for targeting VRK proteins to enter the endocytic-
lysosomal pathway [12], as shown by its sensitivity to chloroquine.
VRK1 plays an early role in cell cycle progression [34]; and VRK2
regulates signal transduction in response to hypoxia [32] or
interleukin-1b [35] by interaction with components of MAP kinase
pathways.
In this work we have analyzed the contribution of acetyl
transferases cofactors to regulate the induction by p53 of this
VRK1 downregulatory effect. The relevance of p53 transcription-
al specificity is manifested by the observation that overexpression
of p300 or CBP can block the effect of p53, but the PCAF
coactivator does not. This might be due to the promoter specificity
of different p53-transcriptional cofactor complexes [36]. But
PCAF and p300 do not compete for the same cofactor; since the
p300 protective effect is detected even in the presence of excess
PCAF. This p300 inhibitory competition of VRK1 downregula-
tion is independent of acetyl transferase activity, since it is blocked
by proteins that do not have the acetyl transferase activity as is the
case for the C/H3 region of p300. Also the downregulatory
mechanism does not require p53 acetylation since it is also induced
by a p53 protein containing all its acetylation sites replaced. The
inhibitory mechanism can be explained by a competition for
binding to p53 by proteins containing a C/H3 domain, such as
p300/CBP. Other acetyl transferase such as PCAF, lacking a C/
H3 domain, has no effect. The C/H3 domain depletes the p53
molecules needed for induction of VRK1 downregulation. The C/
H3 domain of p300/CBP proteins is an interaction region known
to bind to several transcription factors such as MyoD, Fos, c-Jun,
or E2F and to viral proteins such as adenovirus E1A or SV40 large
antigen [18], and also to the transactivation domain of p53.
Functionally, these interactions have been shown to have
competing effects, thus C/H3 mediates a stimulation of c-Fos
that is blocked by binding to E1A [37]. The inhibitory effect of
p300/CBP, or their isolated C/H3 domain, is the consequence of
a successful competition for p53, because of its direct interaction,
which is also required for the transcriptional complex of p53
needed to induce the indirect downregulation of VRK1. This
competition effect is lost in the presence of the C/H3Del33
defective domain, or by PCAF that does not have a C/H3 region.
Mechanistically these observations are consistent with a dominant
negative role for the C/H3 domain [38–40].
The interaction of p53 with these cofactors is affected by the
residue phosphorylated [41]; for example, Ser15 phosphorylation,
or its aspartic substitution, favors binding to p300; while its
substitution by alanine results in a much weaker interaction [42].
The association with these cofactors in transcriptional complexes is
Figure 8. p53 also induces downregulation of VRK2 isoforms that is protected by p300 and is sensitive to chloroquine. (A). Effect of
p300 on VRK2A or VRK2B downregulation. H1299 cells were transfected with pCB6+p53 (0.2 mg) and 5 mg of pCEFL-HA-VRK2A or pCEFL-HA-VRK2B
plasmids. p300 was expressed from increasing amounts (mg) of plasmid. VRK2 and p300 were detected with an anti-HA antibody. The quantification
of normalized levels of VRK2A and VRK2B are shown at the bottom. (B). Effect of chloroquine, an inhibitor of the endosome-lysosome vesicle
transport. Cells were transfected with plasmids as indicated. The quantification of normalized levels of VRK2A and VRK2B are shown at the bottom.
doi:10.1371/journal.pone.0002649.g008
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ations determine p300 and CBP specificity [43] in processes such as
in myogenesis [44]; p300/CBP modulates the BRCA1 inhibition of
estrogen receptor [45], and downregulation of p300/CBP activates
a senescence checkpoint in melanocytes [46]. PCAF, but not p300/
CBP, acetylates the transcription factor Fetal-Kruppel-like factor
(FKLF2) [47]. PCAF acetylates PTEN and reduces its ability to
down-regulate phosphatidylinositol 3-kinase signalingand to induce
G1 cell cycle arrest [48]. But also p300 and PCAF can cooperate in
activation in Notch responses [49]; and both p300/CBP and PCAF
can acetylate p53 in response to DNA damage [50]. Also CBP and
PCAF can acetylate MyoD increasing its transcriptional activity
[51]. Differential effects of p53 cofactors have also been reported in
the apoptotic response that requires p300 but not CBP [52] in
response to ionizing radiation [53]. In the context of cancer, it is
important to note that, in the presence of activated H-Ras or N-Ras
oncogenes, an active degradation of p300 is induced [54], and this
change will permit the activation and subsequent degradation of
VRK1 by the new complexes of p53. Among the genes regulated by
p53 there is a clear candidate to be implicated in this process. The
expression of DRAM is positively regulated by p53, and encodes a
lysosomal protein implicated in degradation of stable proteins [55],
as is the case of VRK1 [34]. VRK1 degradation is promoted by
DRAM (unpublished results). Inducible active degradation of stable
proteins is an important step in biological processes such as
autophagy [55].
Target selection by transcriptional complexes, in which proteins
such as p53 or transcriptional cofactors with acetyl transferaseactivity
Figure 9. Mapping in VRK1 and VRK2 the regions needed for degradation. (A). Three deletion constructs of human VRK1 were tested for
their sensitivity to induction of degradation by p53. Linear sequence motifs were identified using the ELM program (Eukaryotic Linear Motif program)
available from the European Molecular Biology Laboratory. End. Sequence for endosomal target motif (grey horizontal boxes); LysEnd: sequence for
lysosomal-endosomal target motif (black boxes). The VRK1 truncation constructs were detected with an antibody recognizing the myc epitope used
as tag. (B). Identification of target sequences in VRK2 to enter the degradation pathway induced by p53 and its protection conferred by the C/H3
domain of p300. VRK2 was detected with an anti-HA antibody. The C/H3 domain of p300 was detected with an anti-Flag antibody.
doi:10.1371/journal.pone.0002649.g009
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intracellular concentrations of these proteins; and depending on
their intracellular concentrations, one or another group of genes may
be stimulated. However, the role of relative changes in factor
concentration has so far received little attention, in comparison with
all or none effects, despite their very important physiological
relevance. The effect of changing levels of p300/CBP on the
induction of VRK1 proteolytic downregulation, requiring p53
dependent transcription as an intermediate step, can be considered
in this context of factor competition. Thus the downregulation of
VRK1 is not only determined by the level of p53, but VRK1
downregulation is also conditioned by the relative levels of different
acetyl transferases present in the cell. It is highly likely that the
heterogeneity of effects frequently observed in response to common
types of stimulation is precisely reflecting differences in the
intracellular balance of the proteins implicated.
Materials and Methods
Plasmids, antibodies and reagents
The VRK1 construct, pCEFL-HA-VRK1, coding for the wild
type VRK1 has been previously described [5]. Similarly pCEFL-
HA-VRK2 (A and B) has been reported [31]. The N-terminal
region of VRK1 (residues 1–267), lacking the exposed endocytic
targeting region was cloned in pCDNA3.1 as a KpnI-XhoI
fragment. The plasmid pCB6+p53 and its different phosphoryla-
tion mutants [25] and the acetylation mutant p53-6KR were from
Dr. K. Vousden (The Beatson Institute, Glasgow); plasmid
pCMVb-p300-CHA was from Richard Eckner (University of
Zurich, Switzerland); and plasmids p300-C/H3-Flag and p300-C/
H3Del33-Flag were from J. DeCaprio (Harvard University,
Boston, MA) [17]; plasmid pCI-FLAG-PCAF was from Y.
Nakatani (Dana Farber Cancer Institute, Boston). pSG5-CBP
was from D. Heery (Nottingham University, UK). Plasmid
pCEFL-HA-TSG101 was made by subcloning human TSG101
cDNA in vector pCEFL-HA (S. Blanco, unpublished). All plasmids
used for transfection were endotoxin free and purified with the
JetStar Maxi kit from Genomed (Bad Oeynhausen, Germany).
VRK1 was detected using a rabbit polyclonal antibody (VE1), or
a mouse monoclonal antibody (1F6 clone), made against a VRK1
fusion protein [13]. VRK2 isoforms were detected with a specific
polyclonal antibody [31]. A mouse monoclonal antibody HA-probe
(F7) against the HA tag was from Covance (Berkeley). The p53
protein was detected with a mixture of DO1 antibody (Santa Cruz,
CA) and Pab1801 (Santa Cruz, CA) used at 1:500 and 1:1000
respectively. p300 was detected with RW128 monoclonal antibody
(Upstate, Lake Placid, NY). CBP was detected with sc-583 rabbit
polyclonal antibody (Santa Cruz). The anti b-actin (AC-15)
antibody was from Sigma. As secondary antibody a Goat anti-
mouse-HRP and Goat anti-rabbit-HRP (Amersham Pharmacia
Biotech) were used at 1:5000 in immunoblots.
Cell lines and transfections
The human lung cancer cell line H1299 (p53
2/2)w a sg r o w ni n
RPMI supplemented with 10% fetal calf serum, glutamine, penicillin
and streptomycin in a humidified atmosphere and 5% CO2.F o r
transfection experiments H1299 cells were plated in 60 or 100 mm
dishes and transfected with the plasmid indicated in the specific
experiments with JetPEI reagent following manufacturer’s instruc-
tions (Polytransfection, Illkirch, France). The cells were, unless
otherwise indicated, lysed 36 hours postransfection, in lysis buffer
(Tris-HCl 50 mM pH 8, 150 mM NaCl, 5 mM EDTA and
1%Triton X-100 plus protease and phosphatase inhibitors) and
25 mg of whole cell extract were processed for SDS-PAGE and
subject to immunoblotting with the indicated antibodies. Where
indicated, chloroquine, aninhibitor ofendosome-lysosome fusion was
added at the indicated concentration twelve hours after transfection
and cells were lysed after an additional twenty-four hours.
Immunoprecipitations
Whole cell extracts (1 mg) were precleared by incubation with
50 ml of Gamma-Bind G Sepharose beads (GE Healthcare) for
30 min at 4uC and washed 3 times in lysis buffer (10 mM EDTA,
10% Glycerol, 140 mM NaCl, 1% NP40, 20 mM TrisHCl
pH 8.0). The corresponding antibody was added to the cleared
cell extract and incubated overnight with rotation at 4uC. Next
40 ml of Gamma-Bind G Sepharose beads blocked with PBS and
1% BSA were added and incubated for 4 hours at 4uC. The beads
were washed five times in lysis buffer[13]. The washed beads were
used for loading gels and immunoblot analysis.
Immunoblots
Total protein extracts were quantified using a BIORAD Protein
assay kit (Biorad, Hercules, CA). Proteins were fractionated in an
SDS-polyacrylamide gel and transferred to a PVDF Immobilon-P
membrane (Millipore). The membrane was blocked with TBS-T
buffer (25 mM Tris, 50 mM NaCl, 2.5 mM KCl, 0.1% Tween-20)
and 5% defatted-milk. Afterwards the filter was rinsed with TBS-T
buffer and the specific primary antibody (indicated in individual
experiments) added and incubated for 90 minutes at room
temperature. The filter was rinsed and incubated with a secondary
antibody conjugated with peroxidase for 30 minutes. The mem-
brane was develop for chemiluminescence with the ECL reagent
(Amersham, Little Chalfont, UK) and exposed to X-ray films (Fuji).
To detect high molecular proteins such as p300 or CBP, a 5%
PAGE was run at low voltage for 5 hours, running out of the gel
lower molecular size proteins up to 250 kDa. The proteins were
transferred in buffer (25 mM TrisHCl, 192 mM glycine) with 10%
methanol overnight at 4uC. The detection of p300 and CBP were
detected with the indicated antibodies. All experiments were
performed three times and all immunoblots were quantified in the
linear response range; however in figures is shown a representative
western blot and its quantification.
Acknowledgments
The technical assistance by Virginia Gasco ´n is greatly appreciated.
Author Contributions
Conceived and designed the experiments: PAL AV. Performed the
experiments: AV SB FMV. Analyzed the data: PAL AV SB FMV. Wrote
the paper: PAL.
References
1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The
protein kinase complement of the human genome. Science 298: 1912–1934.
2. Nezu J, Oku A, Jones MH, Shimane M (1997) Identification of two novel human
putative serine/threonine kinases, VRK1 and VRK2, with structural similarity
to vaccinia virus B1R kinase. Genomics 45: 327–331.
3. Vega FM, Gonzalo P, Gaspar ML, Lazo PA (2003) Expression of the VRK
(vaccinia-related kinase) gene family of p53 regulators in murine hematopoietic
development. FEBS Lett 544: 176–180.
4. Santos CR, Rodriguez-Pinilla M, Vega FM, Rodriguez-Peralto JL, Blanco S, et
al. (2006) VRK1 Signaling Pathway in the Context of the Proliferation
p300 Prevents VRK1 Degradation
PLoS ONE | www.plosone.org 10 July 2008 | Volume 3 | Issue 7 | e2649Phenotype in Head and Neck Squamous Cell Carcinoma. Mol Cancer Res 4:
177–185.
5. Vega FM, Sevilla A, Lazo PA (2004) p53 Stabilization and Accumulation
Induced by Human Vaccinia-Related Kinase 1. Mol Cell Biol 24: 10366–10380.
6. Kamath RS, Fraser AG, Dong Y, Poulin G, Durbin R, et al. (2003) Systematic
functional analysis of the Caenorhabditis elegans genome using RNAi. Nature
421: 231–237.
7. Lopez-Borges S, Lazo PA (2000) The human vaccinia-related kinase 1 (VRK1)
phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour
suppressor protein. Oncogene 19: 3656–3664.
8. Barcia R, Lopez-Borges S, Vega FM, Lazo PA (2002) Kinetic Properties of p53
Phosphorylation by the Human Vaccinia-Related Kinase 1. Arch Biochem
Biophys 399: 1–5.
9. Dornan D, Hupp TR (2001) Inhibition of p53-dependent transcription by BOX-
I phospho-peptide mimetics that bind to p300. EMBO Rep 2: 139–144.
10. Jabbur JR, Tabor AD, Cheng X, Wang H, Uesugi M, et al. (2002) Mdm-2
binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption
between the p53 residues Thr18 and Asp21. Oncogene 21: 7100–7113.
11. Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1:
1001–1008.
12. Valbuena A, Vega FM, Blanco S, Lazo PA (2006) p53 Downregulates Its
Activating Vaccinia-Related Kinase 1, Forming a New Autoregulatory Loop.
Mol Cell Biol 26: 4782–4793.
13. Valbuena A, Lopez-Sanchez I, Vega FM, Sevilla A, Sanz-Garcia M, et al. (2007)
Identification of a dominant epitope in human vaccinia-related kinase 1 (VRK1)
and detection of different intracellular subpopulations. Arch Biochem Biophys
465: 219–226.
14. Grossman SR (2001) p300/CBP/p53 interaction and regulation of the p53
response. Eur J Biochem 268: 2773–2778.
15. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, et al. (1998) DNA damage
activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:
2831–2841.
16. Roy S, Tenniswood M (2007) Site-specific acetylation of p53 directs selective
transcription complex assembly. J Biol Chem 282: 4765–4771.
17. Borger DR, DeCaprio JA (2006) Targeting of p300/CREB Binding Protein
Coactivators by Simian Virus 40 Is Mediated through p53. J Virol 80:
4292–4303.
18. Patel D, Huang SM, Baglia LA, McCance DJ (1999) The E6 protein of human
papillomavirus type 16 binds to and inhibits co-activation by CBP and p300.
Embo J 18: 5061–5072.
19. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, et al. (2001) p300/CBP-
mediated p53 acetylation is commonly induced by p53-activating agents and
inhibited by MDM2. Embo J 20: 1331–1340.
20. Ferrer M, Lopez-Borges S, Lazo PA (1999) Expression of a new isoform of the
tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt
lymphoma cell lines. Oncogene 18: 2253–2259.
21. Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigen-
esis. Nat Rev Cancer 4: 793–805.
22. Meek DW (2004) The p53 response to DNA damage. DNA Repair (Amst) 3:
1049–1056.
23. Jackson MW, Agarwal MK, Agarwal ML, Agarwal A, Stanhope-Baker P, et al.
(2004) Limited role of N-terminal phosphoserine residues in the activation of
transcription by p53. Oncogene 23: 4477–4487.
24. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, et al. (2004)
Phosphorylation of p53 on key serines is dispensable for transcriptional
activation and apoptosis. J Biol Chem 279: 53015–53022.
25. Ashcroft M, Kubbutat MH, Vousden KH (1999) Regulation of p53 function and
stability by phosphorylation. Mol Cell Biol 19: 1751–1758.
26. Roemer K, Mueller-Lantzsch N (1996) p53 transactivation domain mutant Q22,
S23 is impaired for repression of promoters and mediation of apoptosis.
Oncogene 12: 2069–2079.
27. Giles RH, Peters DJ, Breuning MH (1998) Conjunction dysfunction: CBP/p300
in human disease. Trends Genet 14: 178–183.
28. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, et al. (1998) p300/
MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 2:
405–415.
29. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, et al. (2005) p53
isoforms can regulate p53 transcriptional activity. Genes Dev.
30. Boehden GS, Akyuz N, Roemer K, Wiesmuller L (2003) p53 mutated in the
transactivation domain retains regulatory functions in homology-directed
double-strand break repair. Oncogene 22: 4111–4117.
31. Blanco S, Klimcakova L, Vega FM, Lazo PA (2006) The subcellular localization
of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on
p53 stability in tumour cell lines. Febs J 273: 2487–2504.
32. Blanco S, Santos C, Lazo PA (2007) Vaccinia-Related Kinase 2 Modulates the
Stress Response to Hypoxia Mediated by TAK1. Mol Cell Biol 27: 7273–7283.
33. Valbuena A, Suarez-Gauthier A, Lopez-Rios F, Lopez-Encuentra A, Blanco S,
et al. (2007) Alteration of the VRK1-p53 autoregulatory loop in human lung
carcinomas. Lung Cancer 58: 303–309.
34. Valbuena A, Lopez-Sanchez I, Lazo PA (2008) Human VRK1 Is an Early
Response Gene and Its Loss Causes a Block in Cell Cycle Progression. PLoS
ONE 3: e1642.
35. Blanco S, Sanz-Garcia M, Santos CR, Lazo PA (2008) Modulation of
Interleukin-1 Transcriptional Response by the Interaction between VRK2 and
the JIP1 Scaffold Protein. PLoS ONE 3: e1660.
36. Espinosa JM, Verdun RE, Emerson BM (2003) p53 functions through stress-
and promoter-specific recruitment of transcription initiation components before
and after DNA damage. Mol Cell 12: 1015–1027.
37. Bannister AJ, Kouzarides T (1995) CBP-induced stimulation of c-Fos activity is
abrogated by E1A. Embo J 14: 4758–4762.
38. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, et al. (1997)
Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:
1175–1184.
39. Puri PL, Avantaggiati ML, Balsano C, Sang N, Graessmann A, et al. (1997)
p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene
transcription. Embo J 16: 369–383.
40. Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, et al. (1997)
Differential roles of p300 and PCAF acetyltransferases in muscle differentiation.
Mol Cell 1: 35–45.
41. Buschmann T, Adler V, Matusevich E, Fuchs SY, Ronai Z (2000) p53
phosphorylation and association with murine double minute 2, c-Jun NH2-
terminal kinase, p14ARF, and p300/CBP during the cell cycle and after
exposure to ultraviolet irradiation. Cancer Res 60: 896–900.
42. Dumaz N, Meek DW (1999) Serine15 phosphorylation stimulates p53
transactivation but does not directly influence interaction with HDM2. Embo J
18: 7002–7010.
43. Kalkhoven E (2004) CBP and p300: HATs for different occasions. Biochem
Pharmacol 68: 1145–1155.
44. Roth JF, Shikama N, Henzen C, Desbaillets I, Lutz W, et al. (2003) Differential
role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream
of MyoD and Myf5. Embo J 22: 5186–5196.
45. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, et al. (2002) p300 Modulates the
BRCA1 inhibition of estrogen receptor activity. Cancer Res 62: 141–151.
46. Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, et al. (2002)
Down-regulation of p300/CBP histone acetyltransferase activates a senescence
checkpoint in human melanocytes. Cancer Res 62: 6231–6239.
47. Song CZ, Keller K, Murata K, Asano H, Stamatoyannopoulos G (2002)
Functional interaction between coactivators CBP/p300, PCAF, and transcrip-
tion factor FKLF2. J Biol Chem 277: 7029–7036.
48. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, et al.
(2006) PCAF modulates PTEN activity. J Biol Chem 281: 26562–26568.
49. Wallberg AE, Pedersen K, Lendahl U, Roeder RG (2002) p300 and PCAF act
cooperatively to mediate transcriptional activation from chromatin templates by
notch intracellular domains in vitro. Mol Cell Biol 22: 7812–7819.
50. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, et al. (1999) p53
sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to
DNA damage. Mol Cell Biol 19: 1202–1209.
51. Polesskaya A, Duquet A, Naguibneva I, Weise C, Vervisch A, et al. (2000)
CREB-binding protein/p300 activates MyoD by acetylation. J Biol Chem 275:
34359–34364.
52. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, et al. (1999) Function
for p300 and not CBP in the apoptotic response to DNA damage. Oncogene 18:
5714–5717.
53. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, et al. (1999) Role for
p300 in stabilization of p53 in the response to DNA damage. J Biol Chem 274:
1883–1886.
54. Sanchez-Molina S, Oliva JL, Garcia-Vargas S, Valls E, Rojas JM, et al. (2006)
The histone acetyltransferases CBP/p300 are degraded in NIH 3T3 cells by
activation of Ras signalling pathway. Biochem J 398: 215–224.
55. Crighton D, Wilkinson S, O’Prey J, Syed N, Smith P, et al. (2006) DRAM, a
p53-induced modulator of autophagy, is critical for apoptosis. Cell 126:
121–134.
p300 Prevents VRK1 Degradation
PLoS ONE | www.plosone.org 11 July 2008 | Volume 3 | Issue 7 | e2649